Scar - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 90
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: SF501F8A8E0EN
Leaflet:

Download PDF Leaflet

Scar - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Scar - Pipeline Review, H2 2016’, provides an overview of the Scar pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Scar, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Scar and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Scar
  • The report reviews pipeline therapeutics for Scar by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Scar therapeutics and enlists all their major and minor projects
  • The report assesses Scar therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Scar
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Scar
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Scar pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Scar Overview
Therapeutics Development
Pipeline Products for Scar - Overview
Pipeline Products for Scar - Comparative Analysis
Scar - Therapeutics under Development by Companies
Scar - Therapeutics under Investigation by Universities/Institutes
Scar - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Scar - Products under Development by Companies
Scar - Products under Investigation by Universities/Institutes
Scar - Companies Involved in Therapeutics Development
3M DRUG DELIVERY SYSTEMS
Albireo AB
Altacor Limited
Beech Tree Labs, Inc.
Clanotech AB
Escape Therapeutics, Inc.
FirstString Research, Inc.
LegoChem Biosciences, Inc
Moerae Matrix, Inc.
Promore Pharma
RXi Pharmaceuticals Corporation
VBS Pharmaceuticals
Scar - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
A-3914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-5425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BTL-slo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLT-28643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Beta 2 Receptor for Wound Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FibroStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Granexin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICX-RHY - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LCB-030110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MG-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MMI-0100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nefopam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OLX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide for Wounds and Scars - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Scar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXI-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-34240 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tranilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Scar - Dormant Projects
Scar - Discontinued Products
Scar - Product Development Milestones
Featured News & Press Releases
Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream
Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model
Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109
Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications
Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference
Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics
Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting
Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO
Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference
Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301
Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Scar, H2 2016
Number of Products under Development for Scar - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Scar - Pipeline by 3M Drug Delivery Systems, H2 2016
Scar - Pipeline by Albireo AB, H2 2016
Scar - Pipeline by Altacor Limited, H2 2016
Scar - Pipeline by Beech Tree Labs, Inc., H2 2016
Scar - Pipeline by Clanotech AB, H2 2016
Scar - Pipeline by Escape Therapeutics, Inc., H2 2016
Scar - Pipeline by FirstString Research, Inc., H2 2016
Scar - Pipeline by LegoChem Biosciences, Inc, H2 2016
Scar - Pipeline by Moerae Matrix, Inc., H2 2016
Scar - Pipeline by Promore Pharma, H2 2016
Scar - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Scar - Pipeline by VBS Pharmaceuticals, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Scar - Dormant Projects, H2 2016
Scar - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Scar, H2 2016
Number of Products under Development for Scar - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

3M Drug Delivery Systems
Albireo AB
Altacor Limited
Beech Tree Labs, Inc.
Clanotech AB
Escape Therapeutics, Inc.
FirstString Research, Inc.
LegoChem Biosciences, Inc
Moerae Matrix, Inc.
Promore Pharma
RXi Pharmaceuticals Corporation
VBS Pharmaceuticals
Skip to top


Ask Your Question

Scar - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: